TRAILBLAZER-ALZ 2: Among patients with early symptomatic #AlzheimerDisease and amyloid and tau pathology, donanemab treatment significantly slowed clinical progression at 76 weeks.
https://t.co/evvC0dvxrh
#AAIC23
Tröscher et al. show that in patients with GAD65 antibody-associated temporal lobe epilepsy, cytotoxic T cells attack and kill neurons and are responsible for the early neuronal loss. https://t.co/9buT7VWUdd
🥁PAPER ALERT🥁
🚨 What’s the risk of #seizure relapse after postsurgical antiseizure medication withdrawal?
With data from 9 #epilepsy centers, we built models to predict individualized outcomes.
@GalovicMarian@UCLIoN@yesILAE
Our findings 🧵
https://t.co/MbqnLXnhnT
Our latest research on the varying characteristics of 2 subtypes of paraneoplastic cerebellar degeneration is available here in PubMed: https://t.co/pI4c4YBZFb
#Neurotwitter#PNS#neuroscience
Happy and proud to share our new study on neuropathological characteristics of PCD subtypes with anti–P/Q-VGCC versus anti-Yo autoantibodies. Thanks indeed to all collaborators! Please find the article here: https://t.co/47Ht2nFT5L. #Neurology#NeuroTwitter#PCD#PNS@MedUni_Wien
This study compares neuropathologic characteristics of PCD with anti–P/Q-VGCC and anti-Yo autoantibodies in an archival autopsy cohort. Read the open access article now: https://t.co/8pEYq8ANMu #Neurology#NeuroTwitter
Such an honor to see our article on PCD subtypes as the July 2022 cover image in Neurol Neuroimmunol Neuroinflamm @GreenJournal: https://t.co/47Ht2nFT5L!🤩Thanks indeed to the editors, contributors and particularly Dr Takashi Irioka and my PI Prof Romana Höftberger. #NeuroTwitter
@obenaufa@IMPvienna Congratulations and thank you so much again for the fantastic and inspiring Keynote Lecture at the @MedUni_Wien YSA PhD Symposium 2022!